BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

182 related articles for article (PubMed ID: 11910651)

  • 1. Comparison of the efficacy and endometrial safety of two estradiol valerate/dienogest combinations and Kliogest for continuous combined hormone replacement therapy in postmenopausal women.
    Gräser T; Koytchev R; Müller A; Oettel M
    Climacteric; 2000 Jun; 3(2):109-18. PubMed ID: 11910651
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical efficacy and safety of combined estradiol valerate and dienogest: a new no-bleed treatment.
    von Schoultz B
    Climacteric; 2003 Aug; 6 Suppl 2():24-32. PubMed ID: 14669841
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Climodien (estradiol valerate 2 mg plus dienogest 2 mg) is safe and effective in the treatment of postmenopausal complaints.
    Gräser T; Römer T; Wiedey KD; Janaud A
    Climacteric; 2001 Dec; 4(4):332-42. PubMed ID: 11770190
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Estradiol valerate/dienogest.
    Wellington K; Perry CM
    Drugs; 2002; 62(3):491-504; discussion 505-6. PubMed ID: 11827562
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Impact on uterine bleeding and endometrial thickness: tibolone compared with continuous combined estradiol and norethisterone acetate replacement therapy.
    Dören M; Rübig A; Coelingh Bennink HJ; Holzgreve W
    Menopause; 1999; 6(4):299-306. PubMed ID: 10614676
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A comparative 2-year study of the effects of sequential regimens of 1 mg 17beta-estradiol and trimegestone with a regimen containing estradiol valerate and norethisterone on the bleeding profile and endometrial safety in postmenopausal women.
    Koninckx PR; Spielmann D
    Gynecol Endocrinol; 2005 Aug; 21(2):82-9. PubMed ID: 16294460
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Hormone replacement therapy and vigilance: double-blind, placebo-controlled EEG-mapping studies with an estrogen-progestogen combination (Climodien, Lafamme) versus estrogen alone in menopausal syndrome patients.
    Saletu B; Anderer P; Gruber D; Metka M; Huber J; Saletu-Zyhlarz GM
    Maturitas; 2002 Nov; 43(3):165-81. PubMed ID: 12443834
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of long-term continuous combined hormone replacement therapy with estradiol valerate and either dienogest or norethisterone acetate on mammographic density in postmenopausal women.
    Georgiev DB; Manassiev NA
    Medscape Womens Health; 2002; 7(4):1. PubMed ID: 12466733
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Sleep, vigilance and cognition in postmenopausal women: placebo-controlled studies with 2 mg estradiol valerate, with and without 3 mg dienogest.
    Saletu B
    Climacteric; 2003 Aug; 6 Suppl 2():37-45. PubMed ID: 14669843
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of combined oral estrogen/progestogen preparation (Kliogest) on bone mineral density, plasma lipids and postmenopausal symptoms in HRT-naïve Thai women.
    Jirapinyo M; Theppisai U; Manonai J; Suchartwatnachai C; Jorgensen LN
    Acta Obstet Gynecol Scand; 2003 Sep; 82(9):857-66. PubMed ID: 12911449
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The role of antiandrogens in hormone replacement therapy.
    Schneider HP
    Climacteric; 2000 Dec; 3 Suppl 2():21-7. PubMed ID: 11379383
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy and Safety of Estradiol Valerate/Dienogest for the Management of Heavy Menstrual Bleeding: A Multicenter, Double-Blind, Randomized, Placebo-Controlled, Phase III Clinical Trial.
    Yu Q; Zhou Y; Suturina L; Jaisamrarn U; Lu D; Parke S
    J Womens Health (Larchmt); 2018 Oct; 27(10):1225-1232. PubMed ID: 29957101
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The endometrial response to sequential and continuous combined oestrogen-progestogen replacement therapy.
    Sturdee DW; Ulrich LG; Barlow DH; Wells M; Campbell MJ; Vessey MP; Nielsen B; Anderson MC; Bragg AJ
    BJOG; 2000 Nov; 107(11):1392-400. PubMed ID: 11117768
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Insomnia related to postmenopausal syndrome and hormone replacement therapy: sleep laboratory studies on baseline differences between patients and controls and double-blind, placebo-controlled investigations on the effects of a novel estrogen-progestogen combination (Climodien, Lafamme) versus estrogen alone.
    Saletu-Zyhlarz G; Anderer P; Gruber G; Mandl M; Gruber D; Metka M; Huber J; Oettel M; Gräser T; Abu-Bakr MH; Grätzhofer E; Saletu B
    J Sleep Res; 2003 Sep; 12(3):239-54. PubMed ID: 12941063
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effects of hormone replacement therapy on perceptual and cognitive event-related potentials in menopausal insomnia.
    Anderer P; Semlitsch HV; Saletu B; Saletu-Zyhlarz G; Gruber D; Metka M; Huber J; Gräser T; Oettel M
    Psychoneuroendocrinology; 2003 Apr; 28(3):419-45. PubMed ID: 12573306
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Endometrial safety, overall safety and tolerability of transdermal continuous combined hormone replacement therapy over 96 weeks: a randomized open-label study.
    Samsioe G; Boschitsch E; Concin H; De Geyter C; Ehrenborg A; Heikkinen J; Hobson R; Arguinzoniz M; Ibarra de Palacios P; Scheurer C; Schmidt G;
    Climacteric; 2006 Oct; 9(5):368-79. PubMed ID: 17080587
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Breast cell proliferation in postmenopausal women during HRT evaluated through fine needle aspiration cytology.
    Conner P; Söderqvist G; Skoog L; Gräser T; Walter F; Tani E; Carlström K; von Schoultz B
    Breast Cancer Res Treat; 2003 Mar; 78(2):159-65. PubMed ID: 12725416
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Endometrial safety and tolerability of triphasic sequential hormone replacement estradiol valerate/medroxyprogesterone acetate therapy regimen.
    Rees MC; Kuhl H; Engelstein M; Mattila L; Mäenpää J; Mustonen M;
    Climacteric; 2004 Mar; 7(1):23-32. PubMed ID: 15259280
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effect on endometrium of long term treatment with continuous combined oestrogen-progestogen replacement therapy: follow up study.
    Wells M; Sturdee DW; Barlow DH; Ulrich LG; O'Brien K; Campbell MJ; Vessey MP; Bragg AJ
    BMJ; 2002 Aug; 325(7358):239. PubMed ID: 12153918
    [TBL] [Abstract][Full Text] [Related]  

  • 20. One-year randomized study of the endometrial safety and bleeding pattern of 0.25 mg drospirenone/0.5 mg 17β-estradiol in postmenopausal women.
    Genazzani AR; Schmelter T; Schaefers M; Gerlinger C; Gude K
    Climacteric; 2013 Aug; 16(4):490-8. PubMed ID: 23531117
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.